Latest Breaking News On - Intranasal foralumab - Page 1 : comparemela.com

Tiziana Life Sciences Ltd : Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Tiziana Life Sciences Ltd : Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Indiens wirtschaftIhre chancenGabriele cerronePaul spencerTanuja chitnisIrina kofflerWilliama clementiTiziana life sciences ltdHome dosing initiativeProfessor of neurology at harvard medical schoolDrug administrationTiziana life sciencesBusiness developmentLifesci advisorsAt home dosingSafety exposure

Tiziana Life Sciences (TLSA) Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Tiziana Life Sciences (TLSA) Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Williama clementiTanuja chitnisGabriele cerroneTiziana life sciencesTiziana life sciences ltdDrug administrationProfessor of neurology at harvard medical schoolIntranasal foralumabTiziana lifeDelivery device trainingChief development officerMass general brighamPrincipal investigatorHarvard medical schoolMass general brigham healthcare

Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing .

Williama clementiIrina kofflerTanuja chitnisPaul spencerGabriele cerroneProfessor of neurology at harvard medical schoolTiziana life sciencesTiziana life sciences ltdDrug administrationBusiness developmentHome dosing initiativeLifesci advisorsAt home dosingSafety exposureHas beenHome dosing likely

Tiziana Life Sciences Reports Positive 6-month Data With Intranasal Foralumab In Multiple Sclerosis

Tiziana Life Sciences Ltd. (TLSA), a clinical-stage biopharmaceutical company, announced Monday positive six-month clinical results in multiple sclerosis patients treated with intranasal Foralumab.

Gabriele cerroneAccess programMore such health newsResearch of multiple sclerosis onTiziana life sciencesTiziana life sciences ltdEuropean committee for treatmentModified fatigue impact scaleSecondary progressive multiple sclerosisExpanded accessEuropean committeeMultiple sclerosisTiziana life sciencesIntranasal foralumab

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Irina kofflerPaul spencerTiziana life sciences ltdResearch in multiple sclerosisResearch of multiple sclerosisBusiness developmentTiziana life sciencesLifesci advisorsEuropean committee for treatmentAnnounces presentationSix month safetyBiomarker dataIntranasal foralumabSix non active secondary progressiveLife sciencesEuropean committee